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being equally affected 1）. PWS was first described by 
Prader et al. in 1956 2）and the clinical manifestations 
of PWS include hypotonia, early childhood-onset 
hyperphagia, characteristic facial appearance, hypogo-
nadism, growth hormone deficiency, mild-to-severe 
mental retardation, and behavioral disturbance 3）.
Although patients with PWS are characterized by 
feeding difficulties and poor growth until 9 months of 
age, they tend to be obese thereafter owing to hyper-
phagia and lack of satiety caused by the dysregulation 
of hypothalamic pituitary. PWS is often complicated 
by severe obesity and type-2 diabetes mellitus
INTRODUCTION
The estimated prevalence of Prader-Willi Syndrome
（PWS）is 1 in 10,000−30,000 with males and females 
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SUMMARY
Purpose：To investigate and compare features of diabetic retinopathy（DR）in patients with Prader-Wil-
li Syndrome（PWS）and those without PWS.
Methods：Overall, 33 PWS patients with type-2 diabetes mellitus（T2DM）secondary to PWS（65 eyes）
and 55 age-matched patients with T2DM（109 eyes）without congenital heredity diseases were reviewed. 
Medical records of 65 eyes with PWS（PWS group：mean age 24.7±5.9 years）and 109 eyes without PWS
（control group：mean age 22.9±6.2 years）were acquired and compared from January 2000 to November 
2018. Best-corrected visual acuity（BCVA）was determined and DR scores were assigned.
Results：BCVA was significantly low in PWS group compared with the controls（P＜0.001）. Pseudopha-
kia was frequently observed in patients in the PWS group（P＝0.024）. No significant differences were 
found with respect to cataract（P＝0.065）and DR score（P＝0.77）between patients in the PWS and con-
trol groups. Investigations into the possible causes of the low BCVA in the PWS group found no significant 
difference regarding strabismus（P＝0.065）. However, significant differences were found between both 
groups with respect to amblyopia（P＜0.01）. Visual acuity examinations were incomplete in some patients 
with PWS because of their inability to concentrate（P＜0.01）.
Conclusions：There was no correlation between DR progression and PWS. Lower BCVA in PWS 
patients was likely owing to amblyopia and incomplete visual acuity examination owing to inability of 
patients with PWS to concentrate.
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（T2DM）4）and the latter often leads to diabetic reti-
nopathy（DR）. The rate of T2DM incidence is 26.2％
（17/65 patients）in Japanese PWS patients aged ＞10 
years 5）.
Strict control of blood sugar is difficult for patients 
with PWS owing to their mental retardation and 
abnormal behavior. Hori et al. reported that diagnos-
ing and treating DR in patients with PWS is challeng-
ing owing to low levels of cooperation 6）. It may thus 
be hypothesized that diabetic retinopathy（DR）in 
PWS patients is more severe and visual acuity is 
poorer than in diabetic patients without PWS. Owing 
to the scarcity of studies regarding DR in PWS 
patients, we aimed to advance knowledge in this area 
by comparing DR in T2DM patients with PWS to 
that in age-matched T2DM patients without PWS.
METHODS
The study was approved by the Institutional 
Review Board of Dokkyo Medical University Saitama 
Medical Center and adhered to the tenets of the Dec-
laration of Helsinki. Informed consent was obtained 
from all participants.
The medical records of 33 patients（65 eyes）who 
were diagnosed with T2DM secondary to PWS（PWS 
group：25 males and 8 females）between January 
2000 and November 2018 in the pediatrics division of 
Dokkyo Medical University Saitama Medical Center 
were reviewed in this study. The PWS group com-
prised 25 males and 8 females with a mean age of 24.7
±5.9 years. Two eyes in the PWS group were vitrec-
tomized under local anesthesia at another clinic in this 
study. Overall, 55 age-matched T2DM patients with-
out PWS（109 eyes）comprising 35 males and 20 
females（22.9±6.2 years）identified during the same 
time period formed the control group；patients in the 
control group were not diagnosed with other congeni-
tal diseases or mental retardation. Diagnostic methods 
employed for T2DM and PWS were as previously 
reported 5）. PWS was diagnosed by polymerase chain 
reaction（PCR）analysis；abnormal methylation was 
observed. The 15q11-q13 deletion was detected by 
fluorescence in situ hybridization using specific 
probes. Uniparental disomy（UPD）was detected by 
PCR using established methods targeting polymorphic 
DNA microsatellites in the chromosomal 15q11-q13 
region. T2DM was diagnosed according to the criteria 
established in the Classification and Diagnostic Crite-
ria of Diabetes Mellitus by the Committee of the 
Japan Diabetes Society in 1999. In brief, a diagnosis of 
T2DM was made if any of the following criteria were 
met：1）fasting plasma glucose（FPG）≥ 126 mg/dl 
and/or a plasma glucose level in the 2-hour oral glu-
cose tolerance test（2hPG）≥ 200 mg/dl（with 75 g glu-
cose）, and/or casual plasma glucose（CPG）≥ 200 mg/
dl detected on ≥ 2 occasions；2）FPG ≥ 126 mg/dl, 
and/or 2hPG ≥ 200 mg/dl, and/or CPG ≥ 200 mg/dl 
are measured at least once, accompanied by typical 
diabetic symptoms, and/or HbA1c ≥ 6.5％ , and/or 
DR7）.
At the initial examination, all patients underwent 
comprehensive ophthalmologic examinations, which 
included standardized refraction, measurement of 
best-corrected visual acuity（BCVA）using a Landolt 
ring, slit-lamp biomicroscopy, and fundus examination 
after mydriasis. Color fundus photography and fluores-
cein angiography were performed as needed. Eyes 
with DR were classified according to Fukuda’s new 
classification 8）. For convenience, we assigned non-DR 
a score of 0 , simple DR（Fukuda A1 and A2）was 
assigned 1 , interrupted proliferative DR（Fukuda 
A3-A5）as score 2, mild malignant DR（Fukuda B1 
and B2）as score 3, and severe malignant retinopathy
（Fukuda B3-B5）as score 4 8）. Complications, such as 
macular edema, tractional retinal detachment, neovas-
cular glaucoma, and ischemic optic neuropathy were 
not assigned any scores 8）. Decimal VA data were con-
verted to a logarithm of the minimum angle of resolu-
tion（logMAR）. Objective refractive status was mea-
sured using autorefractometers . The manifest 
spherical equivalent（SE）value was calculated as the 
spherical power plus half the cylindrical power.
All data were expressed as mean±standard devia-
tion. Differences between the PWS and control groups 
in the variables of age, logMAR BCVA, DR score, 
spherical power, cylindrical power, and SE were com-
pared using unpaired t-tests. Discrete variables 
between the 2 groups were compared using the chi-
square test or Fisher’s exact probability test. Statisti-
cal analyses were performed using StatMate version 
V for Macintosh（ATMS, Tokyo, Japan）. A P value of
＜0.05 was considered statistically significant.
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RESULTS
Patient demographics are summarized in Table 1. 
There were no statistically significant differences in 
the age and sex distributions between T2DM patients 
with PWS and those without PWS. Complications such 
as macular lesions, tractional retinal detachment, neo-
vascular glaucoma, or ischemic optic neuropathy were 
not reported in any patient.
Log MAR BCVA was significantly worse in the 
PWS group than in the control group（P＜0.001, Fig-
ure 1）. Among T2DM patients in the PWS group, 3 
eyes had pseudophakia（P＝0.024 , Table 2）and 2 
eyes had slight cataracts（P＝0.065, Table 2）com-
pared with none in the control group. The DR score 
was 0.12±0.42 for the PWS group and 0.15±0.64 for 
the control group；no significant differences in DR 
scores were observed between the 2 groups（P＝0.77, 
Figure 2）. Although there were no differences in the 
DR scores between PWS patients and controls, there 
was a significant difference in BCVA.
We further analyzed the factors contributing to this 
Fig. 1
LogMAR best-corrected visual acuity（BCVA）is 
significantly better（P＜0.001 in the control group 
than in the PWS（Prader-Willi Syndrome）group.
PWS             Control        
*
*P < 0.001
0.10 ± 0.29 -0.056 ± 0.12 
Table 1　 Age and sex distribution of patients with 
Prader-Willi Syndrome and controls
Factor
PWS
（n＝33）
Control
（n＝65） P Value
Age（years） 24.7±5.9 22.9±6.2 0.17＊
Sex（Male, Female） 25, 8 35, 20 0.24†
PWS：Prader-Willi Syndrome
Data are shown as means±SDs.
＊ Unpaired t-test, †chi-square test.
Table 2　Ophthalmic factors of patients with Prader-Willi Syndrome and controls
Factor
PWS
（n＝65）
Control
（n＝109） P Value
IOL/pseudophakia（Y, N） 3, 62 0, 109  　0.024†
Cataracts（Y, N） 2, 63 0, 109  　0.065†
‡, ＊＊Strabismus（Esotropia）（Y, N） 2, 31 0, 55  　0.065†
‡, ＊＊Nystagmus（Y, N） 1, 32 0, 55 　0.19†
‡Amblyopia（Y, N） 9, 56 2, 107 ＜0.01†
Concentration deficiency（Y, N） 5, 60 0, 109 ＜0.01†
Spherical power −2.66±3.76 −1.81±2.89  　0.098＊
Cylindrical power −1.61±1.45 −0.89±1.02  ＜0.001＊
SE −3.47±3.99 −2.26±3.06  　0.042＊
PWS：Prader-Willi Syndrome, IOL：intraocular lens, Y：yes, N：no
SE：manifest spherical equivalent
＊Unpaired t-test, †chi-square test.
‡Overlaps included.
＊＊PWS（n＝33）, Control（n＝55）
Data are shown as mean±SD.
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contradiction. Two eyes had esotropia and one had 
nystagmus in the PWS group, but no eyes with stra-
bismus and nystagmus were observed in the control 
group（P＝0.065 and P＝0.19, respectively, Table 2）. 
Nine eyes had amblyopia that in the PWS group, 
whereas only 2 eyes had amblyopia in the control 
group and reached statistical significance（P＜0.01, 
Table 2）. Of the 9 amblyopic eyes in the PWS group, 
4 had ametropic amblyopia, 3 had anisometropic 
amblyopia, and 2 had strabismic amblyopia, whereas 
both amblyopic eyes in the control group had aniso-
metropic amblyopia（Table 3）. Examination of visual 
acuity was incomplete for 5 eyes in the PWS group 
owing to patient’s lack of concentration during the 
procedure, whereas it was completed for all eyes in 
the control group（P＜0.01 , Table 2）. Refraction, 
except pseudophakia, was analyzed and significant dif-
ferences were observed between the PWS and control 
groups with respect to SE（−3.47±3.99 and −2.26±
3.06, respectively；P＝0.042）and cylindrical power
（−1.61±1.45 and −0.89±1.02 , respectively；P＜
0.001）（Table 2）. However, spherical power（−2.66±
3.76 and −1.81±2.89 for the PWS and control groups, 
respectively）was not significantly different（P＝0.098, 
Table 2）.
DISCUSSION
It is difficult for patients with PWS to cooperate 
during the ophthalmological examinations and treat-
ments owing to mild-to-severe mental retardation. 
Therefore, it is believed that the diagnosis and initia-
tion of the treatment of DR generally tends to be late 
in patients with PWS6）. However, the progression of 
DR in PWS patients in this study was similar to that 
of control patients with T2DM who did not have PWS 
and mental retardation. At least, the discovery of DR 
in PWS was not delayed. However, some patients with 
PWS could not complete the visual acuity examination 
and faced challenges in performing fundus check, fluo-
rescein angiography, laser treatment, intravitreal 
injection of anti-vascular endothelial growth factor or 
vitrectomy in such situations. Nevertheless, laser 
treatment 9）and vitrectomy under local 6）or general 10）
anesthesia for proliferative DR in PWS have been pre-
viously reported.
Although the lifespan of patients with PWS is not 
well understood owing to limited studies, the severity 
of obesity and diabetes may affect it 11）. Severe obesity 
sometimes causes Pickwickian syndrome and the 
patient might die of heart failure at a young age 12〜14）. 
Advances in PWS therapy may, in future, increase 
the lifespan of patients with PWS. Conversely, living 
longer may increase the chance of DR progression；
therefore, ophthalmological examination and treatment 
are essential and cooperation from patients is critical. 
Despite the availability of simple and rapid ophthalmo-
logical examination and treatments, problems may 
arise if ophthalmologists and ophthalmological assis-
tants fail to elicit cooperation and communicate effec-
tively with non-cooperative patients.
Amblyopia is generally diagnosed during childhood 
and can be treated using eyeglasses and eye patches, 
however, mental retardation of patients restricts the 
use of eyeglasses and eye patches. Significant differ-
ences in cylindrical power and SE, but not in spherical 
power, were observed between the PWS and control 
groups likely because 2 eyes in the PWS group had 
ametropic amblyopia caused by high astigmatism. 
This observation concurs with the findings of Hered 
Fig. 2
Diabetic retinopathy（DR）score was not significantly 
different（P＝0.77）between PWS and controls.
PWS               Control        
0.12 ± 0.42 
0.15 ± 0.64 
P = 0.77
ns Table 3　Detail of amblyopia in both groups
Type of amblyopia PWS Control
Ametropic 4 0
Anisometropic 3 2
Strabismic 2 0
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RW et al. who reported that 7 patients（15％）with 
PWS had a myopia refractive error of ＞−3.75 diop-
ters（D）, and 19（41％）had astigmatism of ＞1.25D15）. 
The prevalence of strabismus is 2.1％−3.3％ in the 
normal population 16）. Strabismus（esotropia）was 
noted in 2 of the 65 eyes（3.1％ of PWS group）in this 
study. Although we only analyzed patients with PWS 
and T2DM, further analysis should be performed in 
all patients with PWS regardless of their diabetic sta-
tus. The prevalence of strabismus ranges from 16.7％ 
to 95％ in patients with PWS15,17〜20）. Taken together, 
strabismus generally seems to be more frequent in 
patients with PWS than normal individuals. Creel et 
al. reported that nystagmus was a characteristic fea-
ture in PWS21）. Hered et al. did not find nystagmus in 
46 patients with PWS 15）, and Roy et al. observed 2 
cases of nystagmus in 10 patients with PWS20）. Nys-
tagmus was observed in only 1 of the 33 patients in 
the PWS group in this study and no significant differ-
ence was observed between the 2 groups. Therefore, 
based on our results, a definite correlation between 
nystagmus and PWS cannot be derived. To the best 
of our knowledge, there are no reports about the rea-
son about amblyopia, strabismus and nystagmus are 
frequent in patients with PWS than normal individu-
als.
In this study, 2 eyes had cortical cataracts and 3 
eyes had pseudophakia in the PWS group. Among 
these, one eye received cataract surgery alone, where-
as the remaining received vitrectomy and cataract 
surgery simultaneously under local anesthesia at 
another clinic. Although it is difficult to draw a conclu-
sion because DM sometimes causes cataracts in young 
age, the correlation between PWS and cataracts 
observed in this study is plausible and is supported 
by published reports on PWS and cataracts 20, 22）.This 
study has several limitations. First, the sample size 
was relatively small. Only 33 patients who had T2DM 
secondary to PWS underwent ophthalmological exami-
nations. Because young T2DM patients were rare, 
only 55 patients were included as controls. Second, 
the limited observation period in this study may have 
obscured clinically important findings that may be 
unmasked in an extended study.
Although the diagnosis and treatment of DR in 
patients with PWS are thought to be late in general, 
we found that the diagnosis of DR was not late in this 
study. Because visual acuity examinations were 
incomplete in some cases owing to the lack of concen-
tration during ophthalmological examination and treat-
ment, non-invasive and rapid procedures and thera-
pies are warranted for patients with PWS.
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